Nanotechnology based platforms for survivin targeted drug discovery

Samarasinghe, Rasika M., Gibbons, Jessica, Kanwar, Rupinder K. and Kanwar, Jagat R. 2012, Nanotechnology based platforms for survivin targeted drug discovery, Expert opinion on drug discovery, vol. 7, no. 11, pp. 1083-1092, doi: 10.1517/17460441.2012.719869.

Attached Files
Name Description MIMEType Size Downloads

Title Nanotechnology based platforms for survivin targeted drug discovery
Author(s) Samarasinghe, Rasika M.
Gibbons, Jessica
Kanwar, Rupinder K.
Kanwar, Jagat R.ORCID iD for Kanwar, Jagat R.
Journal name Expert opinion on drug discovery
Volume number 7
Issue number 11
Start page 1083
End page 1092
Total pages 10
Publisher Informa Healthcare
Place of publication London, England
Publication date 2012-11
ISSN 1746-0441
Keyword(s) cancer
Summary Introduction: Development of an effective, safe and targeted drug delivery system to fight cancer and other diseases is a prime focus in the area of drug discovery. The emerging field of nanotechnology has revolutionised the way cancer therapy and diagnosis is achieved primarily due to the recent advances in material engineering and drug availability. Further, the recognition of the crucial role played by anti-apoptotic proteins such as survivin, has initiated the development of therapeutics that can target this protein as an attempt to develop alternative cancer therapies. However, a key challenge faced in drug development is the efficient delivery of survivin-targeted molecules to specific areas in the body.Areas covered: This review primarily focuses on the different strategies employing nanotechnology for targeting survivin expressed in human cancers. Different nanomaterials incorporating nucleic molecules or drugs targeted at survivin are discussed and the results obtained from studies are highlighted.Expert opinion: There are extensive studies reporting different treatment regimens for cancer, however, they still result in systemic toxicity, reduced bioavailability and ineffective delivery. Novel approaches involve the use of biocompatible nanomaterials together with gene or drug molecules to target proteins such as survivin, which is overexpressed in cancerous cells. These nanoformulations allow the benefits of protecting easily degradable molecules, allow controlled release, and enhance targeted delivery and effectiveness. Hence, nanotherapy utilizing survivin targeting can be considered to play a key role in the development of personalized nanomedicine for cancer.
Language eng
DOI 10.1517/17460441.2012.719869
Field of Research 100709 Nanomedicine
100708 Nanomaterials
111204 Cancer Therapy (excl Chemotherapy and Radiation Therapy)
Socio Economic Objective 920102 Cancer and Related Disorders
HERDC Research category C1 Refereed article in a scholarly journal
Persistent URL

Document type: Journal Article
Collection: Institute for Frontier Materials
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 10 times in TR Web of Science
Scopus Citation Count Cited 12 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 313 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Wed, 13 Mar 2013, 09:15:26 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact